Cytomegalovirus Infections Clinical Trials

18 recruiting

Cytomegalovirus Infections Trials at a Glance

19 actively recruiting trials for cytomegalovirus infections are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Suzhou, Philadelphia, and Paris. Lead sponsors running cytomegalovirus infections studies include Assistance Publique - Hôpitaux de Paris, The First Affiliated Hospital of Soochow University, and Centre Hospitalier Universitaire de Saint Etienne.

Browse cytomegalovirus infections trials by phase

Treatments under study

About Cytomegalovirus Infections Clinical Trials

Looking for clinical trials for Cytomegalovirus Infections? There are currently 18 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cytomegalovirus Infections trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cytomegalovirus Infections clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 119 of 19 trials

Recruiting

Breakthrough CMV Lung Transplant -Multicentre

Cytomegalovirus Infections
University of Alberta40 enrolled1 locationNCT04439916
Recruiting
Not Applicable

Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT

Cytomegalovirus InfectionsCMV
The First Affiliated Hospital of Soochow University330 enrolled1 locationNCT06812598
Recruiting
Not Applicable

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

Kidney Transplantation, Cytomegalovirus InfectionsEBV InfectionAntiviral Prophylaxis
National Taiwan University Hospital80 enrolled1 locationNCT07294547
Recruiting
Early Phase 1

T Cell Therapy of Opportunistic Cytomegalovirus Infection

Hematopoietic Stem Cell TransplantCytomegalovirus InfectionsOpportunistic Infections
Mari Dallas20 enrolled1 locationNCT02982902
Recruiting
Phase 3

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Cytomegalovirus InfectionsKidney Transplant InfectionPancreas Transplant
University of Wisconsin, Madison90 enrolled1 locationNCT06407232
Recruiting

Evaluation of Software for Interpreting Virological Results Indicated for the Diagnosis of Cytomegalovirus (CMV) Infection During Pregnancy and Intended for Health Professionals

Cytomegalovirus InfectionsMaternal Primary Cytomegalovirus Infection
Assistance Publique - Hôpitaux de Paris491 enrolled2 locationsNCT06694428
Recruiting
Phase 1Phase 2

Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

Epstein-Barr Virus InfectionsCytomegalovirus InfectionsAdenovirus
Jessie L. Alexander25 enrolled3 locationsNCT06909110
Recruiting
Phase 2

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

Cytomegalovirus InfectionsPrimary Immune Deficiency Disorder
New York Medical College20 enrolled9 locationsNCT03266640
Recruiting

Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Cytomegalovirus InfectionsImmunoglobulin Prophylaxis
Antonello Di Paolo, M.D., Ph.D.150 enrolled1 locationNCT07013370
Recruiting
Phase 2

Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

Cytomegalovirus InfectionsTransplant-Related Disorder
University of Pennsylvania80 enrolled1 locationNCT06066957
Recruiting
Not Applicable

QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis

Cytomegalovirus Infections
Centre Hospitalier Universitaire de Saint Etienne196 enrolled2 locationsNCT04030676
Recruiting
Phase 4

Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

NeutropeniaCytomegalovirus InfectionsInfection in Solid Organ Transplant Recipients+1 more
Tufts Medical Center25 enrolled1 locationNCT05626530
Recruiting
Phase 2

A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®

Cytomegalovirus InfectionsAdenovirus InfectionEBV+2 more
University Hospital, Basel, Switzerland30 enrolled1 locationNCT02007356
Recruiting
Phase 1

R-MVST Cells for Treatment of Viral Infections

Epstein-Barr Virus InfectionsCytomegalovirus InfectionsBK Virus Infection+1 more
Columbia University36 enrolled1 locationNCT05183490
Recruiting
Phase 2

ATG Individualized Dosing Model in URD-PBSCT.

Stem Cell Transplant ComplicationsCytomegalovirus InfectionsInfection Reactivation
Chinese PLA General Hospital30 enrolled1 locationNCT06572462
Recruiting
Not Applicable

Quantiferon CMV to Identify Treatment Need for Asymptomatic CMV Infection After Solid Organ Transplant (QUANTIFOT)

Heart TransplantationCytomegalovirus InfectionsKidney Transplantation
University Hospital, Grenoble288 enrolled1 locationNCT06341543
Recruiting

Evaluation of CMV/EBV-CMI in Haploid HSCT

Epstein-Barr Virus InfectionsHematopoietic Stem Cell TransplantationCytomegalovirus Infections
The First Affiliated Hospital of Soochow University60 enrolled1 locationNCT06554197
Recruiting

Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study

Cytomegalovirus Infections
University of Massachusetts, Worcester100 enrolled1 locationNCT06522880
Recruiting

Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis

Acute LeukemiaCytomegalovirus Infections
Assistance Publique - Hôpitaux de Paris250 enrolled3 locationsNCT06058858